The BvgAS phosphorelay regulates ∼10% of the annotated genomes of Bordetella pertussis and Bordetella bronchiseptica and controls their infectious cycles. The hierarchical organization of the regulatory network allows the integration of contextual signals to control all or specific subsets of BvgAS-regulated genes. Here, we characterize a regulatory node involving a type III secretion system (T3SS)-exported protein, BtrA, and demonstrate its role in determining fundamental differences in T3SS phenotypes among Bordetella species. We show that BtrA binds and antagonizes BtrS, a BvgAS-regulated extracytoplasmic function (ECF) sigma factor, to couple the secretory activity of the T3SS apparatus to gene expression. In B. bronchiseptica, a remarkable spectrum of expression states can be resolved by manipulating btrA, encompassing over 80 BtrA-activated loci that include genes encoding toxins, adhesins, and other cell surface proteins, and over 200 BtrA-repressed genes that encode T3SS apparatus components, secretion substrates, the BteA effector, and numerous additional factors. In B. pertussis, BtrA retains activity as a BtrS antagonist and exerts tight negative control over T3SS genes. Most importantly, deletion of btrA in B. pertussis revealed T3SS-mediated, BteA-dependent cytotoxicity, which had previously eluded detection. This effect was observed in laboratory strains and in clinical isolates from a recent California pertussis epidemic. We propose that the BtrA-BtrS regulatory node determines subspecies-specific differences in T3SS expression among Bordetella species and that B. pertussis is capable of expressing a full range of T3SS-dependent phenotypes in the presence of appropriate contextual cues.
T he evolution of the human respiratory pathogen Bordetella pertussis from its broad host range Bordetella bronchisepticalike ancestor was accompanied by genome reduction, a proliferation of pseudogenes, and host restriction (1) (2) (3) . This transition also correlates with a systematic pattern of transcriptional diversity in the BvgAS virulence regulon that we hypothesized was due to functional alterations in regulatory factors that control clusters of loci in a hierarchical network (4) . In B. bronchiseptica and B. pertussis, the transmembrane BvgS histidine kinase and BvgA response regulator coordinate expression of nearly all known colonization and virulence genes, an array of transcriptional regulators, and numerous genes of unknown function (3) (4) (5) (6) . BvgAS establishes a spectrum of phenotypic phases in response to environmental cues, functioning as a rheostat that controls the infectious cycle (7, 8) . The Bvg + phase is characterized by high level BvgAS activity, expression of virulence factors [including pertussis toxin (9) , adenylate cyclase toxin (10, 11) , filamentous hemagglutinin (12) , fimbriae (13) , the Bordetella secretion complex (Bsc) type III secretion system (T3SS Bsc ) (14) (15) (16) ], and the ability to survive and replicate on respiratory epithelia (17) . In the Bvg phase, the BvgAS phosphorelay is quiescent, Bvg + phase genes are silent, and "virulence-repressed genes" are maximally transcribed (4, 17, 18) . These genes include flagella and motility loci in B. bronchiseptica and genes with unknown function in B. pertussis. The roles of BvgAS-regulated genes that are differentially expressed between the Bvg + and Bvg − extremes of the regulatory spectrum are largely unresolved (7, 19) .
In vitro, T3SS Bsc is a particularly conspicuous virulence determinant owing to its ability to induce rapid cytotoxicity in a diverse array of eukaryotic cells, ranging from mammalian to yeast (15, 20) . In vivo studies with B. bronchiseptica show that T3SS Bsc plays an immunomodulatory role that facilitates persistence in the lower respiratory tract (21, 22) . Remarkably, only a single effector, BteA, has been definitively identified as a translocated substrate (15, 16) . In B. bronchiseptica, BteA is necessary and sufficient for cytotoxicity in vitro, and mutations in bteA recapitulate phenotypes associated with deleting the T3SS ATPase gene, bscN (14) (15) (16) .
As a result of their close evolutionary relationship, comparative studies exploiting the experimental tractability of B. bronchiseptica are relevant for understanding B. pertussis (3, 4, 7, 16, (23) (24) (25) . B. bronchiseptica isolates from diverse hosts, including humans, readily display T3SS activity in vitro (20) . In contrast, there are no reports of T3SS-dependent cytotoxicity by B. pertussis, despite the fact that T3SS loci are highly conserved, are functionally interchangeable, and bear the hallmarks of positive selection (3, 16, 25) . Recent studies are beginning to shed light on this paradox. Although T3SS activity is not observed with Significance Bordetella bronchiseptica isolates from diverse hosts, including humans, display potent cytotoxicity against a broad range of mammalian cells, which is dependent on type III secretion system (T3SS) effector BteA. In contrast, neither laboratory nor clinical isolates of Bordetella pertussis have been observed to display T3SS-dependent cytotoxicity, despite the fact that T3SS genes are present, intact, and nearly identical to their B. bronchiseptica counterparts. We have characterized a regulatory node, involving a T3SS-exported anti-σ factor, BtrA, that controls virulence gene expression in Bordetella species. Of particular relevance to human disease, deletion of btrA in B. pertussis derepresses T3SS gene expression and confers readily detectable BteA-dependent cytotoxicity. These observations warrant a reassessment of type III secretion in the pathogenesis and prevention of pertussis.
laboratory-adapted strains, Bsp22, a highly expressed secretion substrate that polymerizes to form a flexible filament connecting the needle to the translocon, has been detected in culture supernatants of B. pertussis clinical isolates (24, 26) . Furthermore, mutations in the B. pertussis bscN allele result in elevated production of proinflammatory cytokines and accelerate clearance from the lungs of aerosol-infected mice (24) . A hypothesis that could explain species-specific differences is that the regulatory module in the BvgAS regulon that includes T3SS loci has diverged with host specificity. Indeed, T3SS activity is controlled at multiple levels. bteA and bsc apparatus genes are transcriptionally activated by an extracytoplasmic function (ECF) sigma factor, BtrS, which is encoded by a BvgAS-activated gene (25) . In addition, the partnerswitching proteins BtrU, BtrV, and BtrW mediate a cycle of serine phosphorylation and dephosphorylation events that gate secretion through the T3SS apparatus (25, 27) .
Here, we characterize a regulatory node involving a T3SS-exported anti-σ factor, BtrA (20, 28) , and demonstrate its activity as a secreted BtrS antagonist that differentially controls expression of nearly 300 genes that define six distinct regulatory modules within the BvgAS virulence regulon. In B. bronchiseptica, the relative levels of BtrA and BtrS determine the magnitude of T3SS activity. In both laboratory and recent clinical isolates of B. pertussis, deletion of btrA derepressess T3SS gene expression and confers readily observable, BteA-dependent cytotoxicity in vitro. Our results show that B. pertussis is capable of expressing the full range of T3SS-dependent phenotypes and that the BtrA regulatory node is a key determinant of species-specific differences in expression. These observations provide the impetus and foundation for a comprehensive assessment of T3SS Bsc in the pathogenesis and prevention of human pertussis.
Results
BtrA Is a T3SS Substrate That Regulates Multiple Virulence Genes. The bsc locus, which includes T3SS apparatus, translocon, and chaperone genes, is flanked by a cluster of regulatory loci that encode BtrS and the BtrUWV partner-switching module (25, 27) (Fig. 1A) . Recent studies implicate BtrA (also called BspR), which is encoded directly upstream of btrS, as an exported substrate of the Bsc T3SS, illustrated in Fig. 1B using B. bronchiseptica strain RB50 grown in vitro under conditions permissive for type III secretion (20, 28) . BtrA and Bsp22, a known T3SS substrate (26) , are exported into supernatants in a manner dependent on the BscN ATPase. Fractionation controls included pertactin (Prn), an OM autotransporter that releases an N-terminal domain after cleavage (29) , and BvgA, a cytoplasmic response regulator. These results confirm that BtrA is an exported T3SS substrate in RB50.
Next, we generated an RB50 derivative with an in-frame deletion in btrA. A readily apparent phenotype was observed in which independently constructed mutants formed small, weakly hemolytic colonies on blood agar in comparison with RB50 (Fig. 1C ). Relative growth rates in shake flask cultures mirrored differences in colony size because the ΔbtrA mutant grew more slowly and reached lower levels in stationary phase than the WT parental strain (Fig. S1A) . Because hemolytic activity, colony morphology, and growth rate are all BvgAS-regulated phenotypes, we compared the effects of deleting btrA on expression of a panel of genes chosen to represent different modules of the BvgAS virulence regulon.
As shown in Fig. 1D , transcript levels of adhesin and toxin genes (fhaB, prn, bipA, and cyaA), T3SS loci (bopN, bsp22, and bteA), btrS, and btrA are highly dependent on BvgS whereas the flagellin locus (flaA) is Bvg-repressed (3). Expression of T3SS genes additionally requires the BtrS sigma factor, and the same is true for btrA. Deletion of btrA resulted in a marked increase in T3SS-associated transcripts, with induction ratios ranging from 10-fold (bscN) to 34-fold (bteA). In contrast, toxin and adhesin genes showed the opposite effect and were down-regulated 7-fold (cyaA) to 20-fold (fhaB) in ΔbtrA mutants. Interestingly, flaA expression was increased in the ΔbtrA strain to levels similar to the ΔbvgS mutant. As shown in Fig. S1B , these transcriptional effects are reflected at the levels of protein expression and secretion. Complementation with btrA reversed the effects of the ΔbtrA deletion on transcription (Fig. 1E ), protein expression, and secretion (Fig. S1C) . In WT RB50, overexpression of btrA decreased expression of T3SS-associated genes but did not confer increased expression of toxin or adhesin loci, suggesting that BtrA levels in RB50 are sufficient for maximal expression under laboratory conditions. Together, these data confirm and extend previously published results (28) and show that BtrA differentially regulates three distinct modules of the BvgAS regulon: (i) Bvg + phase adhesin and toxin genes, which require BtrA for full level expression, (ii) Bvg + phase T3SS loci that require BtrS and are repressed by BtrA, and (iii) the Bvg phase flagellin locus, which is down-regulated by BtrA (Fig. 1G ).
BtrA Is a Secreted BtrS Antagonist. The observations that BtrA and BtrS have opposing effects on T3SS gene expression and that BtrA is itself a T3SS substrate prompted the hypothesis that BtrA antagonizes BtrS. As shown in Fig. 1F , overexpression of btrS in RB50 resulted in elevated levels of btrA, bsp22, and bopN transcription. For the T3SS apparatus components bsp22 and bopN, BtrS overexpression mimicked the effects of deleting btrA. In contrast, cyaA, fhaB, and flaA transcript levels were relatively insensitive to increased BtrS. Corroborating results were obtained by monitoring protein expression and secretion (Fig. S1D ). These data show that high level expression of T3SS genes can be achieved by eliminating BtrA or by overexpressing BtrS, consistent with an antagonistic interaction.
Because ECF sigma factors are often controlled by antagonistic binding partners (i.e., anti-σ factors), we used a multireadout yeast two-hybrid system to determine whether BtrA and BtrS interact ( Fig. 2A and Fig. S2A ). BtrA fused to the Gal4 DNA binding domain strongly interacted with a BtrS-Gal4 activation domain fusion protein, and identical results were observed when bait and prey inserts were swapped. No interactions were detected with negative control constructs encoding fusions with noncytotoxic BteA (BteA644) or Lamin. To determine the relationships between BtrS binding and gene regulation, we examined the ability of a series of truncated BtrA derivatives to interact with BtrS, repress bsp22 and bopN expression, and up-regulate the expression of fhaB. As shown in Fig. 2 B and D, removal of 33, 63, 93, or 123 residues from the BtrA C terminus eliminated the ability to repress bsp22 and bopN and to activate fhaB in the ΔbtrA background. The Δ93 and Δ123 truncations also eliminated BtrS binding ( Fig. 2C and Fig. S2A ), as did two internal deletions. All mutant BtrA proteins were expressed and secreted at levels that corresponded to their ability to repress T3SS gene expression ( Fig. 2B and Fig. S2B ).
As summarized in Fig. 2E , our data resolve three functional regions of BtrA: a C-terminal domain required for transcriptional Yeast diploids were grown on double dropout (DDO) medium lacking leucine and tryptophan, DDO containing the chromogenic substrate X-α-gal and aureobasidin A (DDO X/A), and on quadruple dropout (QDO X/A) medium containing X-α-gal and aureobasidin A but lacking leucine, tryptophan, histidine, and adenine. Binding interactions result in growth on high stringency QDO X/A medium, resistance to aureobasidin A, and α-galactosidase activity indicated (blue). Interaction of SV40 large T antigen with p53 or Lamin served as positive or negative controls, respectively. Noncytotoxic BteA644 also served as a negative control. Representative results from two independent experiments are shown. All interactions were confirmed by swapping bait and prey protein fusions (Fig. S2). (B) qRT-PCR with RNA from indicated strains. Deletion endpoints correspond to amino acid residues in BtrA as shown in D. Fold differences in transcript levels were calculated relative to recA expression. Colored bars represent average values from three independent experiments, and error bars represent ± SEM. Student's t test was used for statistical analysis. For each gene, strains showing significant differences from ΔbtrA/vector are labeled with * (P < 0.01) or ** (P < 0.001). repression and activation, a central region required for BtrS binding, and N-terminal sequences that mediate recognition as a T3SS substrate. BtrS binding is likely required for transcriptional control, but it is clearly not sufficient. A simple hypothesis for the ability of BtrA to activate expression of fhaB and coregulated loci invokes the existence of a BtrS-activated repressor specific for this subset of genes. This model accounts for the observations that BtrS binding is required for both activation and repression by BtrA, and it is supported by RNA-seq analysis.
Effects of BtrA on Cytotoxicity and Virulence. B. bronchiseptica isolates have T3SS-dependent cytotoxic effects on a broad range of cell types (14, 16, 20, 30) . Most respond like HeLa cells (Fig.  3A) , which are efficiently killed by RB50 in a BscN-and BteAdependent manner. In contrast, human pneumocyte-derived A549 cells are unusually resistant to RB50 cytotoxicity through an unknown mechanism (20) (Fig. 3B) . Resistance was reversed, however, by deleting btrA, which resulted in high level BteA-dependent cytotoxicity against HeLa as well as A549 cells. The levels of cell death observed with RB50ΔbtrA are similar to strain Bbr77, which represents a clade of hypercytotoxic B. bronchiseptica isolates from human respiratory infections (20) .
We next used a murine intranasal challenge model to examine the effects of deleting btrA on respiratory colonization and virulence. Groups of C57BL/6NCr mice were intranasally infected with WT or ΔbtrA strains using a protocol that results in infection of the entire respiratory tract by RB50, followed by gradual clearance from the lungs and trachea (31) . Bacterial numbers in the trachea were indistinguishable throughout the course of the experiment (Fig. 3C) . In lungs, the ΔbtrA mutant showed a modest 1-to 2-log decrease in infection levels until the peak at day 7, followed by clearance with similar kinetics as the WT strain RB50. All animals seemed healthy during the course of the experiment.
Surprised by relative lack of a correlation between hypercytotoxicity in vitro (Fig. 3B) and the infection results shown in Fig. 3C , we compared RB50 and the ΔbtrA mutant in an acute respiratory infection model in which the majority of animals become moribund within 1 wk postinoculation (20, 31) . Again, the ΔbtrA mutant was no more virulent than the WT strain (Fig.  S3) . Because eliminating BtrA results in increased T3SS activity and decreased adhesin and toxin expression, these opposing effects and other changes may account for the lack of an overt phenotype. An alternative possibility is that the system is normally derepressed in vivo through active secretion of BtrA, making the ΔbtrA allele superfluous. In either case, it is important to understand the extent to which BtrA differentially regulates gene expression in Bordetella.
BvgAS, BtrS, and BtrA Regulatory Networks. We compared the transcriptomes of RB50 and isogenic ΔbvgS, ΔbtrS, ΔbtrA, and ΔbtrAΔbtrS derivatives using RNA-seq. The transcriptional data were used to generate nonhierarchical clusters, from which four broad groups of coexpressed gene classes were derived (Fig. 4) . Bvg-repressed genes (n = 297) were found in clusters 1 and 2 whereas Bvg-activated genes (n = 242) grouped in clusters 3 and 4. Genes influenced by deletion of btrA (n = 294) were divided between clusters 1, 3, and 4. Network models consistent with observed regulatory profiles are shown in Fig. 4B . Cluster 1 contains 89 genes that are coregulated with the flagellin locus flaA. These loci are minimally expressed in RB50, highly activated in the Bvg phase (ΔbvgS), and activated in the ΔbtrA strain. Although deleting btrS alone has little effect, combining the ΔbtrS and ΔbtrA alleles reverses the ΔbtrA phenotype. Coexpressed genes in cluster 1 encode a large subset of motility and chemotaxis proteins, along with an assortment of predicted surface and regulatory factors (Dataset S1).
Cluster 2 includes 208 Bvg-repressed genes that are maximally expressed in the ΔbvgS strain with no apparent involvement of BtrA or BtrS. These repressed genes include loci encoding ABC transporters, a sulfate transport system, urea uptake and metabolism (32), a host of diverse metabolic functions, and chemotaxis and motility genes distinct from those in cluster 1. The distribution of motility factors between clusters 1 and 2 accounts for the lack of motility in soft agar by the ΔbtrA strain, in which only cluster 1 genes are derepressed, compared with active motility in the ΔbvgS mutant in which all chemotaxis and motility loci are actively transcribed (Fig. S4 and Dataset S1).
The 168 Bvg-activated genes in cluster 3 split into two groups. Cluster 3a loci encode many of the canonical Bordetella virulence determinants and their accessory factors, including FHA (fhaB and -C), adenylate cyclase toxin (cyaA to -E), pertactin (prn), and fimbria (fimA to -D). In addition to their dependency on BvgS, these genes are down-regulated in the ΔbtrA strain, and this phenotype is reversed in the ΔbtrAΔbtrS double mutant. In contrast, cluster 3b genes are Bvg-activated with little if any effect of BtrA or BtrS. The differential effects of BtrA/BtrS on cluster 3a vs. 3b loci are readily apparent in Fig. 4C . Cluster 3b includes numerous T3SS loci that are BtrS-independent. These loci encode structural components of the secretion apparatus (bscC to -F, bscO to -W), proteins involved in controlling secretion activity (btrW, btrV), and other T3SS-associated factors (Dataset S1).
Cluster 4 contains 126 genes that require BtrS for expression and are negatively regulated by BtrA. This cluster divides into two subgroups that differ in their basal levels of expression. As shown in Fig. 4B , cluster 4a loci are poorly transcribed in vitro by WT or ΔbvgS strains whereas cluster 4b loci are expressed by RB50 at relatively high levels and down-regulated in the ΔbvgS mutant. In both cases, transcript levels are substantially increased by deletion of btrA, and this effect is reversed in a ΔbtrAΔbtrS double mutant (Fig. 4 B and C) . Cluster 4a includes 86 genes predicted to encode several autotransporters and ABC transport systems, regulatory proteins, and various metabolic functions. Surprisingly, this cluster also includes the complete set of genes required for pertussis toxin production (ptxA to -E) and secretion (ptlA to -L), which were previously thought to be quiescent in B. bronchiseptica. Cluster 4b includes T3SS loci that encode extracellular components of the translocation needle (bscI to -K, bsp22), the membrane-penetrating translocon and other secreted apparatus components (bopB, -D, and -N) , the BscN ATPase, the BtrU phosphatase, and the BteA effector (Dataset S1).
As shown in Fig. S5 , the effects of overexpressing btrA or btrS corroborate results obtained with deletion mutants. Taken together, transcriptional profiling experiments reveal an unexpected diversity of expression patterns among BvgAS-regulated genes revealed by manipulating BtrA. Given its pervasive effects on gene expression and the observation that the BtrA proteins of B. bronchiseptica and B. pertussis are 93% identical, we tested the possibility that BtrA regulates virulence genes in B. pertussis.
BtrA Controls T3SS-Mediated Cytotoxicity in B. pertussis. As shown in Fig. 5A , deletion of btrA in B. pertussis strain Bp536 derepresses bopB, bopD, bopN, bsp22, bscN, and bteA transcription, and these effects were partially reversed by complementation. Other T3SS genes, fhaB, cyaA, prn, ptxA, and ptlA, were unaffected by btrA deletion or overexpression. Protein expression and secretion assays (Fig. S6A) mirror results obtained by quantitative real-time polymerase chain reaction (qRT-PCR). We conclude that Bp536 has retained BtrA-mediated control of cluster 4b genes encoding T3SS substrates and components whereas BtrA regulation of virulence genes in clusters 3a and 4a has either been lost or is inapparent in vitro. Cluster 3b genes are BtrA-independent in both B. bronchiseptica and B. pertussis.
Having observed that BtrA functions in B. pertussis, we tested the hypothesis that the lack of discernable T3SS-mediated cytotoxicity in vitro reflects an alteration in regulation as opposed to an inability to deploy a functional secretion apparatus. Indeed, Fig. 5B shows a marked, dose-dependent increase in cytotoxicity conferred by deleting btrA, which is reversed by complementation. Reasoning that the cryptic nature of T3SS cytotoxicity is likely due to BtrS antagonism by BtrA, we overexpressed BtrS in Bp536 and, as predicted, observed a level of cell death that was nearly identical to the ΔbtrA mutant (Fig. 5C) .
As previously seen with B. bronchiseptica (Fig. 3A ) (16), high level cytotoxicity by B. pertussis required both the BteA effector and the BscN ATPase (Fig. 5B) . We were intrigued, however, by the ability to detect toxicity by ΔbtrAΔbteA double mutants at high multiplicities of infection (MOIs) or longer time points, but not by ΔbtrAΔbteAΔbscN triple mutants (Fig. 5B) . Although levels were low and did not reach statistical significance at 6 h, they were highly significant at 24 h, providing evidence for the presence of a BteA-independent, T3SS-dependent activity that confers cytotoxic effects after prolonged incubation.
To further assess the relevance of our results, we determined whether low passage clinical isolates representing currently circulating strains also display enhanced cytotoxicity after btrA deletion. B. pertussis strains Bp2 and Bp11 were isolated from lethal infections in infants during the 2010 pertussis epidemic in California, and, although challenging to grow and manipulate, we were able to delete btrA in both strains. This deletion resulted in levels of cytotoxicity similar to those seen with Bp536 (Fig. 5D) , and a corresponding increase in Bsp22 secretion (Fig. S6B ). Cells exposed to B. pertussis isolates with derepressed T3SSs displayed blebbing and other morphological changes characteristic of those seen with WT B. bronchiseptica (Fig. 5E) (30) .
Our data show that BtrA is active in B. pertussis, that B. pertussis is capable of expressing a fully functional Bsc T3SS, and that the lack of cytotoxic activity in vitro is due to BtrA-mediated repression. Although BteA clearly functions as a cytotoxic effector, the observation of BteA-independent, T3SS-dependent cytotoxicity raises the possibility that additional effectors await discovery. The implications of these findings and other results are discussed below.
Discussion
Through its function as a secreted BtrS antagonist, BtrA establishes a feedback loop that couples the activity of the T3SS apparatus with expression of T3SS genes encoding the BteA effector, other secretion substrates, and interacting factors. In B. bronchiseptica, BtrA is also required for high level transcription of genes encoding adenylate cyclase toxin, FHA, fimbria, Prn, SphB1, and numerous other products, establishing a reciprocal relationship between their expression and T3SS activity. Reciprocal control of adhesins and toxins vs. T3SS genes could reflect differential requirements during temporally or spatially distinct stages of infection. An alternative hypothesis is that it functions to facilitate immune evasion. It has previously been suggested that T3SS Bsc may target antigen presenting cells (APCs) that extravagate to the respiratory surface during infection (22, 33) . If true, simultaneous down-regulation of major antigen loci and up-regulation of T3SS genes may combine to suppress antigen processing and the generation of protective immunity. Although both regulatory functions are observed in B. bronchiseptica, adhesin and toxin gene expression have apparently been uncoupled from BtrA control in B. pertussis. This observation correlates with the long term and often asymptomatic association between B. bronchiseptica and natural hosts, in contrast to the acute and immunizing nature of human pertussis (3, 34) .
Considerable evidence supports the conclusion that BtrA functions as a BtrS antagonist. For T3SS genes in cluster 4b, deletions in btrA or btrS have opposing transcriptional effects (Fig. 4) , and btrS overexpression in a WT background mimics the effects of deleting btrA (Fig. 1 E and F and Fig. S5D ). BtrA interacts directly with BtrS using a central domain, and regulation of gene expression requires C-terminal sequences in addition to BtrS binding (Fig. 2) . The BtrA N terminus confers recognition as a secretion substrate, thereby coupling T3SS activity to transcriptional control (Fig. S2B) , and it has also been shown to mediate nuclear localization after translocation into host cells (35) . Secreted antagonists regulate flagellar genes in Salmonella (36, 37) and T3SS loci in Pseudomonas aeruginosa (38) , Yersinia spp. (39) , Shigella (40) , and other bacteria (41) . A unique feature of btrA, however, is the extent and diversity of expression profiles it controls.
Six coexpressed clusters of BtrA-regulated genes can be resolved by comparing WT B. bronchiseptica with ΔbvgS, ΔbtrA, ΔbtrS, and ΔbtrA ΔbtrS derivatives (Fig. 4B) . In several cases, expression profiles predict the existence of new, unidentified control factors. For example, high level expression of cluster 3a genes (e.g., fhaB, cyaA, and prn) is clearly dependent on btrA. This requirement is relieved, however, by simultaneously eliminating btrA and btrS, indicating a negative role for BtrS. Because sigma factors are not generally associated with direct repression, we predict the existence of a BtrSactivated negative regulator (Fig. 4B) . Based on its expression profile, this postulated control factor is likely encoded by a cluster 4 gene.
T3SS loci are distributed between cluster 3b, which contains BvgAS-activated genes that are BtrA-and BtrS-independent, and cluster 4b, which includes loci that require BvgAS and BtrS for transcription and are negatively controlled by BtrA. As shown in Fig. S7 , cluster 3b encodes components of the secretion apparatus, up to and including the BscF needle. Cluster 4b encodes secreted substrates, such as the BteA effector, translocon components, and the Bsp22 filament protein, along with multiple chaperones and the BscN ATPase complex. We have previously shown that the BtrU, -W, and -V partner-switching proteins operate at a posttranslational level to "gate" the secretion apparatus, controlling its function in response to unknown queues (27) . Coupling transcription of genes encoding secreted factors and ancillary systems to T3SS activity via negative control by BtrA presumably ensures the availability of an adequate pool of T3SS substrates to meet demand. Although clusters 3b and 4b together include all known T3SS genes, they also include numerous coregulated loci with unexplored roles in Bordetella-host interactions.
We identified two surprising consequences of deleting btrA in B. bronchiseptica. First, ΔbtrA strains display high level, BtrSdependent expression of flagellar and chemotaxis genes in cluster 1, which were previously assumed to be exclusively expressed in the Bvg-phase (4, 42) . A regulatory scheme that can account for these observations is shown in Fig. 4B although the advantage of activating these loci in the Bvg + phase is unclear given the deleterious effect of flagellar expression on respiratory infection (17) . A second surprise was the observation that deletion of btrA activates expression of ptxA to -E and ptlA to -H genes in cluster 4a, which are homologs of the B. pertussis loci that encode pertussis toxin and the T4SS that exports it (3) . Although all genes in cluster 4 require BvgAS and BtrS for transcription, cluster 4a genes seem to require substantially higher levels of BtrS for expression than cluster 4b genes and therefore appear quiescent in vitro.
Of the estimated 5,072 genes in RB50, 12% (n = 591) are BvgAS-regulated as determined by RNA-seq (Fig. 4) . One half of all BvgAS-regulated genes are also controlled by BtrA, and these genes partition into BtrA-repressed (n = 215) and BtrAactivated (n = 80) loci. The pervasive and complex nature of BtrA-mediated transcriptional control in B. bronchiseptica was unexpected, particularly in light of the relatively modest effects of deleting btrA in murine models of infection. Increased expression of cluster 4 genes and decreased transcription of cluster 3a loci could have net effects that are nearly compensatory during short-term infection, or the ΔbtrA allele may mimic expression levels that normally occur in vivo. Longer time points, competition formats, and other approaches may clarify subtle phenotypes in vivo. In contrast, derepression of T3SS genes by deleting BtrA conferred an increase in BteA-dependent cytotoxicity that was readily apparent, even in cells that are nearly refractory to killing by the WT strain (Fig. 3A) . The magnitude of this effect and the extent to which BtrA controls gene expression in B. bronchiseptica prompted us to explore the possibility that differential regulation might explain the enigma of why T3SS-dependent cytotoxicity has never been reported in B. pertussis (3, 25) .
B. pertussis T3SS loci are clearly responsive to BtrA, and the dichotomy between BtrA-regulated expression of secretion substrates and associated factors vs. BtrA-independent expression of apparatus genes is also conserved. Most importantly, deletion of btrA derepressed T3SS activity in B. pertussis, providing the first clear evidence, to our knowledge, for cytotoxicity dependent on the BteA effector and the BscN ATPase (Fig. 5 B-E) . Overexpression of btrS in Bp536 mimicked the effects of deleting btrA, suggesting that BtrA functions by antagonizing BtrS as it does in B. bronchiseptica. Because Bp536 is a derivative of Tohama I (43), which was isolated in the early 1950s and has been passaged in laboratories ever since, it was essential to determine whether BtrA also controls cytotoxicity in currently circulating strains. Indeed, deletion of btrA in two B. pertussis isolates from infants that died of pertussis during the 2010 California epidemic derepressed cytotoxicity to a similar extent as observed in Bp536, thereby demonstrating the relevance of our observations to understanding human disease. In contrast to B. bronchiseptica, BtrA has little effect on expression of virulence genes that encode CyaA, FHA, Prn, or pertussis toxin in B. pertussis Bp536. As indicated in the regulatory model for genes in cluster 3a (Fig. 4B) , BtrA control could be uncoupled in a single step by mutation of a predicted BtrS-activated negative regulator. Indeed, our previously reported comparative microarray analysis showed that numerous transcriptional regulators that are expressed and BvgAS-regulated in B. bronchiseptica are missing, not transcribed, or present as pseudogenes in B. pertussis (4) .
BtrA establishes a critical regulatory loop in both B. pertussis and B. bronchiseptica. We hypothesize that differences in T3SS activity between these subspecies reflects differential control over the intracellular level of BtrA, which is itself determined by secretion activity. The BtrU, -W, and -V partner-switching proteins likely play a pivotal role (27) , and experiments are underway to understand signals and signaling mechanisms that control their interactions and, consequently, the activity of the secretory apparatus. Regardless of the basis for in vitro differences from B. bronchiseptica, the observation that B. pertussis isolates are fully capable of expressing BteA-mediated cytotoxicity in vitro warrants renewed consideration of the potential role of type III secretion in the pathogenesis and prevention of human pertussis.
Materials and Methods
Bacterial cultures and mammalian cells were grown as previously described (20) and are listed in Table S1 along with plasmids used in the study. Mutants were constructed using allelic exchange as previously described (14, 44) . Immunoblotting, cytotoxicity assays, microscopy, and animal experiments were performed as previously described (20) . All animals were maintained in University of California, Los Angeles animal research facilities according to National Institutes of Health and University of California Institutional Animal Care and Use Committee (IACUC) guidelines. The animal experiments were approved by the UCLA Chancellor's Animal Research Committee. Yeast two-hybrid assays were performed per the manufacturer's instructions (Clontech). RNA extraction and processing, quantitative RT-PCR, RNA-seq library preparation, Illumina sequencing, and the data analysis pipeline are described in SI Materials and Methods. Oligonucleotides used for PCR, RT-PCR, and sequencing are listed in Tables S2 and S3 . The RNA-seq alignment statistics, dataset, and comparative analyses are listed in Table S4 and Dataset S1. RNA-seq data reported in this paper have been deposited in the Sequence Read Archive, www.ncbi.nlm.nih.gov/sra (submission no. SRP064665; NCBI BioProject no. PRJNA296526).
